



7,Jan,2016

Press Release

Nippon Boehringer Ingelheim Co., Ltd.

Astellas Pharma Inc.

Extension of agreement on Telmisartan (Micardis[®] family)

Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono; hereinafter "Nippon Boehringer Ingelheim") and Astellas Pharma Inc. (Head Office: Tokyo; President and CEO: Yoshihiko Hatanaka; hereinafter "Astellas") have decided to extend the agreement pertaining to the sale and co-promotion in Japan for telmisartan (Micardis[®] family). The term of the agreement, which runs to December 31, 2016, will be extended to March 31, 2018.

The Micardis[®] family includes "Micardis[®] Tablets 20mg/40mg/80mg," a long-acting angiotensin II receptor antagonist (generic name: telmisartan), "Micamlo[®] Combination Tablets AP/BP", a combination drug of telmisartan and long-acting calcium channel blocker amlodipine besylate, and "Micombi[®] Combination Tablets AP/BP", a combination drug of telmisartan and thiazide diuretic hydrochlorothiazide, and also includes a combination drug for which the approval application has been submitted in Japan, featuring three ingredients, telmisartan, long-acting calcium channel blocker amlodipine besylate and thiazide diuretic hydrochlorothiazide.

Nippon Boehringer Ingelheim and Astellas remain committed to continuously maximising the value of the Micardis[®] family and further contributing to hypertension treatment.

Reference information

About telmisartan

Telmisartan, a long-acting angiotensin II receptor antagonist discovered and developed by Boehringer Ingelheim, has been approved in over 100 countries around the world including Japan, USA and EU.

In Japan, the Micardis[®] family is manufactured by Nippon Boehringer Ingelheim, distributed by Astellas, and co-promoted by both companies. In Japan, all these drugs are indicated for hypertension.

About Boehringer Ingelheim

The Boehringer Ingelheim group (<http://www.boehringer-ingelheim.com/>) is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. As a holding company, Boehringer Ingelheim Japan, Inc. manages four business segments under the following companies: Nippon Boehringer Ingelheim Co., Ltd. (prescription medicine), SSP CO., LTD. (Consumer Health Care), Boehringer Ingelheim Vetmedica Japan (veterinary medicines), and Boehringer Ingelheim Seiyaku (manufacture of pharmaceutical products). Nippon Boehringer Ingelheim Co., Ltd. provides effective pharmaceutical products in Japan in the areas of cardiovascular, respiratory, diabetes, oncology and the central nervous system, amongst others.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Contacts
Nippon Boehringer Ingelheim Co., Ltd. Communications Dept. TEL:03-6417-2145 FAX:03-5435-2920
Astellas Pharma Inc. Corporate Communications TEL:03-3244-3201 FAX:03-5201-7473

Company Profile

◇ **Nippon Boehringer Ingelheim Co., Ltd.** (www.boehringer-ingelheim.jp)

Established: June 1961

Location of the Head Office:

ThinkPark Tower, 2-1-1 Osaki, Shinagawa-ku, Tokyo

Representative: President and Representative Director Yoshiaki Aono

Sales: 250.9 billion JPY (January-December 2014)

No. of employees: 1,948 (as of December 31, 2014)

Description of business: Research and development, import, manufacture and sale of drugs

Import/export and sale of active pharmaceutical ingredients and intermediates

◇ **Boehringer Ingelheim GmbH** (www.boehringer-ingelheim.com)

Established: 1885

Location: Ingelheim, Federal Republic of Germany

Representative: Chairman of the Board of Managing Directors Dr. Andreas Barner

Sales (consolidated): 13.3 billion euros (January-December 2014)

No. of employees (consolidated): Approximately 47,700

Description of business: Research/development, manufacture and sale of ethical drugs, consumer healthcare products, animal drugs, biopharmaceuticals and chemical products, etc.

Affiliated companies: 146 worldwide

◇ **Astellas Pharma Inc.** (www.astellas.com/jp)

Date of launch: April 2005

Location of the Head Office:

2-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo

Representative: President and Representative Director Yoshihiko Hatanaka

Sales (consolidated): 1,247.3 billion JPY (FY2015:April 1, 2014-March 31,2015)

No. of employees (consolidated): 17,113 (As of March 31, 2015)

Description of business: Manufacture, sale and import/export of ethical drugs, etc.